Latest News - Movement Disorders

Tuesday, October 09, 2018

Positive Two-Year Outcomes for Treatment of Essential Tremor With Focused Ultrasound

Patients with medically refractory essential tremor treated with magnetic resonance-guided focused ultrasound (MRgFUS) thalamotomy had a mean 43.4% reduction in their scores on the Clinical Rating Sca…

Read the full story

Thursday, October 04, 2018

Shortage of Sinemet Attribute to Manufacturing and Forecasting Issues

The carbidopa-levodopa distributed under the brand names Sinemet and Sinemet Plus by Merck &Co. (Kenilworth, NJ) is out of stock and expected to be on back order through the first quarter of 2019.…

Read the full story

Tuesday, September 25, 2018

Smart Phone Tests May Distinguish Parkinson’s from Idiopathic REM Sleep Behavior Disorder

In a paper published in Neurology, researchers report that consumer-grade smartphones can be used to accurately identify patients with Parkinson’s disease (PD) versus those with idiopathic REM s…

Read the full story

Thursday, September 20, 2018

FDA Analysis Finds No New or Unexpected Safety Risks of Pimavanserin:Benefits Outweigh Risks

The Food and Drug Administration (FDA) announced that there are no new safety concerns for pimavanserin (Nuplazid; Acadia Pharma, San Diego, CA). Pimavanserin is approved for the treatment of psychoti…

Read the full story

Friday, September 14, 2018

Assessing Relative Neuropsychologic Performance in Patients with Parkinson’s Requires Comparison to Site-Specific Health Controls

In a study published online in the journal Movement Disorders (September 14, 2018), meta-analysis was used to examine the use of neuropsychologic testing to detect early cognitive impairments in peopl…

Read the full story

Tuesday, August 28, 2018

Criteria for Clinically-Established Early Parkinson’s Disease Published

Using the 2015 clinical diagnostic criteria for Parkinson’s disease (PD), a team of researchers have developed criteria specifically for early Parkinson’s disease, defined as less than 5 y…

Read the full story

Tuesday, August 21, 2018

Safety and Efficacy of Opicapone for Patients With Parkinson’s Disease

Safety and efficacy results for opicapone (Neurocrine Biosciences, San Diego, CA), an investigational treatment for end-of-dose motor symptoms, termed off-time, in patients with Parkinson’s…

Read the full story

Monday, August 20, 2018

Long-Term Safety and Efficacy of Valbenazine for Patients With Tardive Dyskinesia

Long-term results for valbenazine (Ingrezza; Neurocrine Biosciences, San Diego, CA), a treatment for patients with tardive dyskinesia (TD), are being presented at the 2018 World Congress on Parkinson&…

Read the full story

Wednesday, August 15, 2018

Free Online Training for Professionals to Develop Exercise Programs for Those With Parkinson's Disease

An online training program has been launched by the Brain Grant Foundation to help professionals develop safe and effective exercise programming for people living with Parkinson’s disease (PD). …

Read the full story

Wednesday, August 08, 2018

Funding Received for Phase 2 Trial of Xanomeline-Tropsium Chloride

A $42-million financing round has been completed and will be used to finance a phase 2 trial of xanomeline-tropsium chloride (KarXT; Karuna, Boston, MA) for treatment of persons with schizophrenia. …

Read the full story

Wednesday, July 18, 2018

Investigational Tau Modifier Receives Orphan Drug Status for Progressive Supranuclear Palsy

The Food and Drug Administration (FDA) has granted an orphan drug designation to ASN120290 (Asceneuron SA, Lausanne, Switzerland) for the treatment of progressive supranuclear palsy (PSP). In preclini…

Read the full story

Friday, July 13, 2018

IncobotulinumtoxinA Approved for Treatment of Excessive Drooling

The Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for incobotulinumtoxin A (Xeomin; Merz, Raleigh, NC) for the treatment of chronic sialorrhea, …

Read the full story

Friday, June 29, 2018

New Dosing Formulation and Strength for Pimavanserin Approved

The Food and Drug Administration (FDA) has approved a new capsule dose formulation and a new tablet strength of pimavanserin (Nuplazid; Acadia Pharmaceuticals, San Diego, CA). Both the new dose and th…

Read the full story

Tuesday, June 26, 2018

New Monoclonal Antibodies Against Alpha-Synuclein Generated

ProMIS Neurosciences, Inc has announced that numerous antibodies against toxic oligomers of alpha-synuclein, implicated in Parkinson’s disease (PD) have begun the final stage of discovery. Hundr…

Read the full story

Wednesday, June 20, 2018

Impulse Control Disorders More Common in People Who Take Dopamine Agonists

A French study which followed 411 people for an average of three years who had been diagnosed with Parkinson’s disease (PD) within 5 years, has reported an increase in impulse control disorders …

Read the full story
Load More